Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
|
19276375 |
2009 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Improvements in mutational profiling have provided valuable insight, such as the ubiquity of TP53 mutations in HGSOC tumors.
|
31187121 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that gene expression patterns that distinguish omental metastasis from primary epithelial ovarian cancer can be identified and that many of the genes have functions that are biologically consistent with a role in oncogenesis, metastasis, and p53 gene networks.
|
17009964 |
2006 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This gene is one of the keys to clarifying the genetic etiology of epithelial ovarian cancer and particularly CCC, given the low incidence of p53 mutations in this tumor type.
|
9789220 |
1998 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-grade serous ovarian cancer (HG-SOC), a major histologic type of epithelial ovarian cancer (EOC), is a poorly-characterized, heterogeneous and lethal disease where somatic mutations of TP53 are common and inherited loss-of-function mutations in BRCA1/2 predispose to cancer in 9.5-13% of EOC patients.
|
24879340 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1, as well as TP53, can undergo LOH prior to stromal invasion in BRCA1-associated ovarian cancer.
|
10880552 |
2000 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because chemokine network is involved in OC progression, we evaluated associations between chemokine expression and survival in tumor suppressor protein p53 (<i>TP53</i>) wild-type (<i>TP53</i>WT) and mutant (<i>TP53</i>m) OC datasets.
|
30181917 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
|
9214672 |
1997 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
|
12112314 |
2002 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
|
23603558 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of p53 is detected in 30-40% of ovarian carcinoma.
|
12770737 |
2003 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
No correlation was found between p21 and p53 expression. p21 expression is a significant prognostic marker for improved survival in ovarian cancer and is associated with early FIGO stage and zero tumor residues after primary tumor resection.
|
10785471 |
2000 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Age-associated, low frequency TP53 mutations were also found in 100% of peripheral blood samples from 15 women with and without ovarian cancer (none with hematologic disorder).
|
27152024 |
2016 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Tissue sections and corresponding cyst and/or ascitic fluid cells from 79 patients with epithelial ovarian cancer were analyzed immunohistochemically for p53 expression.
|
11125280 |
2001 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined the mutational pattern of the p53 gene in 9 patients with epithelial ovarian cancers using tissue collected from different sites within the same patient.
|
1516069 |
1992 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
|
16364249 |
2006 |
Carcinoma, Ovarian Epithelial
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Pelvic and extrapelvic OVCA implants demonstrated similar patterns of signaling pathway expression and identical p53 mutations.
|
23933223 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53-mutated high-grade ovarian carcinoma.
|
30636633 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To determine the feasibility of mutant p53 as a molecular target for gene therapy in ovarian cancer, we constructed an adenovirus vector containing the wild-type p53 gene.
|
7590467 |
1995 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicated that the aberrations of the p53 gene were common in epithelial ovarian cancers and p53 aberration may occur late during ovarian cancer evolution.
|
7729734 |
1995 |
Carcinoma, Ovarian Epithelial
|
0.500 |
Biomarker
|
disease |
BEFREE |
We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype.
|
11791171 |
2002 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.
|
9143413 |
1997 |
Carcinoma, Ovarian Epithelial
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ovarian cancer is characterized by frequent mutations at TP53.
|
28847989 |
2017 |